ClinicalTrials.gg
RecruitingNCT07212595BRAVE-HEARTUpdated Jul 24, 2026

Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy

A Phase 2 interventional study of Amino Acid infusion and Lactated ringers solution in Acute Kidney Injury and Mechanical Ventilation, sponsored by Dana Fuhrman. Recruiting at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Dana Fuhrman · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
164th of 237
30 · median 67
Started
2026
with 28 others
Phase 2
54 of 370
11 open now
Primary completion
2027-11
later than 51 of 87 live
Registered
347th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 164th largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 54 in phase 2, reaches primary completion later than 51 of the 87 other live ones, and was the 347th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The goal of the BRAVE-HEART study is to learn if an amino acid infusion can reduce the risk of developing acute kidney injury after cardiac surgery in children. The main questions it aims to answer are:

  1. Does an amino acid infusion decrease the number of participants with acute kidney injury?
  2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?

Researchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.

Participants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.

03

Conditions studied

  • Acute Kidney Injury
  • Mechanical Ventilation

Browse trials for

Keywords

  • Cardiac Bypass
  • Pediatric
  • Acute Kidney Injury
  • Amino Acids
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Expected to be at high risk of developing acute kidney injury after cardiac surgery based on Age, The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) score, and anticipated cardiopulmonary bypass time
  • Age less than or equal to 18 years
  • Weight greater than or equal to 5 kilograms

Exclusion criteria

Exclusion Criteria:

  • Preoperative extracorporeal organ support
  • History of chronic kidney disease
  • Known or suspected inborn errors of amino acid metabolism
  • Known to amino acids
  • (AST) or Alanine Aminotransferase (ALT) > 3 times the for age/gender
  • Preterm infants less than 6 months of age who were born at less than 36 weeks gestational age
  • Anuria at the time of randomization
  • Expected use of total parental nutrition (TPN) within the first 72 hours post-operatively
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Acid Acid Infusion

    Amino Acid Infusion for up to 72 hours

    Drug: Amino Acid infusion

  • Placebo comparator
    Placebo Infusion

    Placebo Infusion for up to 72 hours

    Drug: Lactated ringers solution

Interventions

  • DrugAmino AcidsStudies of Amino AcidsAmino Acids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amino acid infusion of 2 grams/kilogram of participant weight/day for up to 72 hours

    Also known as: Trophamine(TM) 10%

  • DrugLactated ringers solution

    Placebo infusion to match the volume of the amino acid infusion in grams/kilogram/day

06

What researchers measure

Primary outcomes

  1. Rate of acute kidney injury on post-operative days 2, 3, or 4

    The rate of participants randomized to the amino acid infusion developing acute kidney injury as defined by Kidney Disease Improving Global Outcomes (KDIGO) as Stage 1, 2, or 3 will be compared to the rate of acute kidney injury in the placebo group

    Time frame: From enrollment to post-operative day 4

  2. Rate of mechanical ventilation at 96 hours post-operatively

    Rate of participants randomized to the amino acid infusion needing invasive mechanical ventilation beyond 96 hours post-operatively from congenital cardiac surgery repair will be compared to the rate from the placebo group.

    Time frame: From enrollment to 96 hours post-operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — With a small data set from a single center, there is a high risk of the participants being able to be re-identified with the details within the data set.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2027, 16 months after the start.

Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 16 months is below that.

Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 8, 2025
StartActual
Jul 8, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07212595
Lead sponsor
Dana Fuhrman
Collaborators
Congenital Heart Alliance of Cincinnati
Responsible party
Dana Fuhrman (Associate Director, Center for Acute Care Nephrology, Children's Hospital Medical Center, Cincinnati) — Sponsor-investigator
First posted
Oct 8, 2025
Start date
Jul 8, 2026
Primary completion
Nov 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Kelli Krallman, RN, BSN, MS
Contact
kelli.krallman@cchmc.org
513-636-4837
Stuart Goldstein, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amino Acids

Start the discussion